Ustekinumab to target granulomatous dermatitis in recalcitrant ulcerative necrobiosis lipoidica: case report and proposed mechanism

Lauren A Hassoun; Raja K Sivamani; Victoria R Sharon; Marc A Silverstein; Barbara A Burrall; Danielle M Tartar

Ustekinumab to target granulomatous dermatitis in recalcitrant ulcerative necrobiosis lipoidica: case report and proposed mechanism

Dermatol Online J. 2017 Jul 15;23(7):13030/qt3k32k916.

Authors

Lauren A Hassoun¹, Raja K Sivamani, Victoria R Sharon, Marc A Silverstein, Barbara A Burrall, Danielle M Tartar

Affiliation

¹ Department of Dermatology, University of California Davis School of Medicine, Sacramento, California.

PMID: 29469709

Abstract

We present a 42-year-old woman with no history of diabetes or glucose intolerance who had a 5-year history of ulcerative necrobiosis lipoidica (NL). Despite failure of multiple medications, she experienced clearing of her ulcers after her treatment was changed to ustekinumab. We discuss our patient's disease course and elaborate upon mechanistic reasons for her improvement related to ustekinumab therapy.

Publication types

Case Reports
Letter

MeSH terms

Adult
Dermatologic Agents / therapeutic use*
Female
Granuloma / drug therapy
Granuloma / etiology
Humans
Interleukin-12 / antagonists & inhibitors
Necrobiosis Lipoidica / complications
Necrobiosis Lipoidica / drug therapy*
Necrobiosis Lipoidica / physiopathology
Skin Ulcer / drug therapy
Skin Ulcer / etiology
Ustekinumab / therapeutic use*

Substances

Dermatologic Agents
Interleukin-12
Ustekinumab